Palvella Unites Nonprofits to Shine Light on Rare Microcystic LMs

WAYNE, PA – March 10, 2026 – Clinical-stage biopharmaceutical company Palvella Therapeutics today launched a major disease awareness campaign, “BEYOND mLM,” aimed at the rare and chronically debilitating condition known as microcystic lymphatic malformations (mLM). The initiative, centered around the new educational website BEYONDmLM.com, represents a significant collaborative effort to support a patient population for which no FDA-approved therapies currently exist.

This campaign is not a solo endeavor. Palvella has brought together a powerful coalition of five leading nonprofit organizations from the lymphatic, vascular, and dermatology fields. This alliance includes the Consortium of iNvestigators of Vascular AnomalieS (CaNVAS), the Lymphangiomatosis & Gorham’s Disease Alliance (LGDA), the Lymphatic Education & Research Network (LE&RN), the Pediatric Dermatology Research Alliance (PeDRA), and VAccess.org. The partnership aims to educate, engage, and empower the more than 30,000 diagnosed patients in the United States who navigate the complexities of mLM, along with their caregivers and healthcare providers.

A United Front Against a Neglected Disease

The strategic value of this multi-stakeholder collaboration cannot be overstated in the world of rare diseases, where information is often scarce and patient communities are fragmented. By joining forces, these organizations bring a wealth of expertise, patient advocacy leadership, and credibility to the campaign, ensuring a broader and more impactful reach than any single entity could achieve alone.

Each partner contributes a unique and vital perspective. CaNVAS brings a multi-institutional research focus, PeDRA adds expertise in pediatric skin conditions, and VAccess.org specializes in improving care coordination. Meanwhile, LGDA and LE&RN represent the powerful voice of the patient community, advocating for research, education, and better outcomes. This collective is designed to build a comprehensive support infrastructure that addresses the multifaceted challenges of living with mLM.

“We are delighted to see Palvella bring together experts and organizations who share a commitment for improving the lives of patients with microcystic lymphatic malformations,” said Dr. Michael Kelly, a pediatric hematologist-oncologist at the Cleveland Clinic’s Vascular Anomalies Program and Executive Director of the LGDA. “Patients with microcystic lymphatic malformations often lack access to educational materials written in a way that is accessible and practical. This effort will help provide valuable resources not only for patients and caregivers, but also for healthcare providers seeking to deepen their understanding of this complex condition.”

The Unseen Burden of Microcystic LMs

For those living with microcystic LMs, the need for such resources is profound. The condition is a genetic disease characterized by malformed lymphatic vessels that can protrude through the skin. This leads to a host of chronic and painful symptoms, including persistent leakage of lymph fluid (lymphorrhea) and bleeding. These open sores create a high risk for recurrent, serious infections that can result in hospitalization.

Often presenting in childhood, the disease is progressive and lifelong, with symptoms worsening over time as the number and size of malformed vessels increase. The impact extends far beyond the physical; the condition carries a significant functional and psychosocial burden, affecting patients’ quality of life, social interactions, and mental well-being. The current treatment landscape offers limited solace. With no FDA-approved therapies, management is focused on controlling symptoms. Options include sclerotherapy—injecting a substance to destroy the malformed vessels—which is often less effective for the small cysts of mLM. Surgery is another option, but complete removal is difficult, and malformations frequently recur. Off-label use of medications like sirolimus, an mTOR inhibitor, has shown some promise but is not a standardized or approved solution.

The “BEYOND mLM” campaign aims to fill this void by providing clear, evidence-based information about the disease's biology and its real-world impact. Through patient stories, expert insights, and tailored resources, the initiative seeks to foster a stronger, more connected community, reduce diagnostic delays, and help patients and caregivers better navigate their treatment journey.

Palvella's Pre-Commercial Play in the Orphan Drug Market

While the campaign's immediate goal is patient empowerment and education, it also represents a shrewd strategic maneuver by Palvella Therapeutics. This initiative is a classic example of a “pre-commercial play” in the highly competitive orphan drug space. By building a well-informed and engaged market years ahead of a potential product launch, the company is laying crucial groundwork for future success.

The timing is no coincidence. Palvella's lead product candidate is QTORIN™ 3.9% rapamycin anhydrous gel, a topical treatment being developed specifically for microcystic LMs. Just weeks ago, on February 24, 2026, the company announced positive topline results from its pivotal Phase 3 SELVA trial. The study met its primary endpoint, demonstrating a statistically significant improvement in patients treated with the gel.

With these promising results in hand, Palvella plans to submit a New Drug Application (NDA) to the FDA in the second half of 2026. If all goes well, the company could see a potential approval for QTORIN™ rapamycin in the first half of 2027, making it the first-ever FDA-approved therapy for mLM. By launching “BEYOND mLM” now, Palvella is not just raising awareness of the disease; it is educating future patients, caregivers, and prescribers about the underlying mTOR pathway that its investigational drug targets.

Paving the Road for a Future Therapy

This market-shaping strategy is backed by significant financial momentum. Palvella's stock (NASDAQ: PVLA) has surged over 400% in the past year, and the company recently raised $230 million in a public offering following its positive Phase 3 data. This capital infusion provides the necessary runway to not only navigate the FDA approval process but also to fund robust pre-commercial activities like the “BEYOND mLM” campaign.

In the rare disease sector, gaining regulatory approval is only half the battle. A new drug's success often hinges on a deep understanding of the patient journey, established relationships with key opinion leaders, and a patient community that is educated about their condition and potential new treatment options. The “BEYOND mLM” campaign addresses all three pillars. By collaborating with trusted nonprofit partners, Palvella is building an ecosystem of support and knowledge that can help accelerate diagnosis and ensure that if and when QTORIN™ rapamycin is approved, the path to patient access is as smooth as possible.

This initiative demonstrates a sophisticated understanding of the modern orphan drug landscape, where corporate success is increasingly intertwined with genuine patient advocacy. By investing in the mLM community long before a product hits the shelves, Palvella is building brand trust and positioning itself not just as a drug developer, but as a committed partner in the fight against a long-neglected rare disease.